A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nigdy wcześniej nie otrzymywałeś terapii CAR T i kwalifikujesz się do jej otrzymania
- •Potwierdzony chłoniak dużych komórek B-owych (różne jego typy)
- •Nowotwór wrócił po pierwszym leczeniu lub nie reaguje na leczenie
- •Widoczne zmiany nowotworowe potwierdzone badaniem PET/CT
- •Ogólny stan zdrowia pozwala na uczestnictwo w badaniu
- •Wystarczająca wydajność nerek, wątroby, serca i płuc
✗ Disqualifies
- •Nie kwalifikujesz się do terapii CAR T z innych powodów medycznych
- •Chłoniak umiejscowiony w mózgu lub jego oponach
- •Inne formy chłoniaka (np. chłoniak Burkitta) lub inne typy nowotworów
- •Były u ciebie inne nowotwory, chyba że minęło co najmniej 2 lata od wyleczenia
- •Masz aktualnie niekontrolowaną infekcję (grzybiczną, bakteryjną, wirusową)
- •Cierpiszna autoimmunologiczną chorobę wymagającą leków immunosupresyjnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (36)
Banner MD Anderson Cancer Center
Gilbert, United States
Honor Health
Scottsdale, United States
Mayo Clinic Arizona
Scottsdale, United States
University of Arkansas
Little Rock, United States
Cedars-Sinai Medical Center
Los Angeles, United States
University of California, Los Angeles (UCLA)
Los Angeles, United States
University of California, Irvine
Orange, United States
University of Colorado
Aurora, United States
Colorado Blood Cancer Institute
Denver, United States
MedStar Georgetown University Hospital
Washington D.C., United States
Mayo Clinic Florida
Jacksonville, United States
AdventHealth
Orlando, United States
Moffitt Cancer Center
Tampa, United States
Northside Hospital
Atlanta, United States
Northwestern
Chicago, United States
University of Chicago
Chicago, United States
University of Iowa
Iowa City, United States
University of Kansas Cancer Center
Westwood, United States
University of Louisville Health
Louisville, United States
Mayo Clinic Rochester
Rochester, United States
University of Nebraska Medical Center (UNMC)
Omaha, United States
Hackensack
Hackensack, United States
Roswell Park Comprehensive Cancer Center
Buffalo, United States
Duke Cancer Institute
Durham, United States
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, United States
Oncology Hematology Care Clinical Trials
Cincinnati, United States
University of Cincinnati
Cincinnati, United States
Cleveland Clinical Taussig Cancer Center
Cleveland, United States
Allegheny Health Network
Pittsburgh, United States
SCRI Oncology Partners
Nashville, United States
St. David's South Austin Medical Center
Austin, United States
University of Texas Southwestern Medical Center
Fort Worth, United States
MD Anderson Cancer Center
Houston, United States
Texas Transplant Institute
San Antonio, United States
Intermountain Healthcare
Salt Lake City, United States
Virginia Oncology Associates
Norfolk, United States
Trial contact
David Shook, MD
Mary Lessig, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.